The present study was designed to investigate the ameliorative potential of spironolactone against diabetic hyperalgesia in mice. Tail ‰ick latency, an index of hyperalgesia, was assessed by analgesiometer. Serum nitrite levels, an index of nitric oxide, were analyzed by Griess reaction. Mice were rendered diabetic with streptozotocin (200 mg kg -1 i.p) and kept for 30 days for development of diabetic pain. Thereafter, spleen homogenate supernatant (SHS) was prepared from the mouse spleen and administered in normal mice for 14 days. In both diabetic and SHS-treated mice a signiˆcant degree of hyperalgesia was developed, suggesting the key role of spleen-derived factor in induction of diabetic pain. Moreover, the levels of nitric oxide were also elevated in 30th day diabetic mice and SHS-treated mice. Administration of spironolactone (7 and 15 mg kg -1 p.o.) signiˆcantly attenuated diabetes-induced decrease of nociceptive threshold and increase of serum nitrite oxide levels. Furthermore, SHS of spironolactone-treated diabetic mice failed to induce hyperalgesia and to increase serum nitrite levels. These results suggest that spironolactone has ameliorative potential in attenuating the hyperalgesia associated with diabetes, which may be possibly mediated through inhibition of release of certain critical factors from spleen.
INTRODUCTION
Diabetic patients frequently exhibit increased responsiveness to noxious stimuli (hyperalgesia) and hyper-responsiveness to normally innocuous stimuli (allodynia) that are often concurrent with a paradoxical loss of stimulus-evoked sensation. 1, 2) Similar to human diabetic pain, animal models such as streptozotocin (STZ)-induced diabetic mice also demonstrate thermal hyperalgesia and mechanical allodynia. 3, 4) Spironolactone is an aldosterone receptor antagonist clinically employed as potassium-sparing diuretic. It has also been used clinically to reduce the mortality incidence in congestive heart failure and myocardial infarction. 5) Besides, it has also been documented to improve endothelial dysfunction 6) and reduce urinary albumin excretion and systolic blood pressure in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. 7) Furthermore, spironolactone has also been documented to ameliorate the glomerular injury in STZ-induced early diabetic renal injury. 8) From our laboratory, it has been reported that splenectomy restores the decrease in antinociceptive eŠect of morphine in diabetic mice, suggesting the interference of spleen factors with pain alteration during diabetes. 9) Very recently it has been reported that spleen-derived factors play a key role in the pathogenesis of diabetic hyperalgesia. 10) Therefore the present study was designed to investigate the ameliorative potential of spironolactone against diabetic hyperalgesia and to investigate its modulatory eŠect on spleen homogenate of diabetic mice.
MATERIALS AND METHODS
Swiss albino mice (20 30 g) of either sex were employed for the present study. STZ (Sigma Aldrich, U.S.A.) was dissolved in 0.1 N citrate buŠer (pH 4.5). The suspension of spironolactone (R.P.G. Life Sciences, Ahmedabad) was made in 0.5％ CMC immediately before use. g) were administered for induction of diabetes. Blood samples were obtained from retro-orbital sinus for glucose estimation. Mice with fasting blood glucose levels ＞14 mmol l -1 day 16 after STZ administration were considered diabetic and were included for further study. The diabetic mice were kept for further 14 days for induction of diabetic hyperalgesia.
Estimation of Blood Glucose
Blood Glucose levels were estimated spectrophotometrically by glucose-oxidase method 11) using a commercially available enzymatic kit.
Measurement of Nociceptive Threshold
Nociceptive threshold was determined by noting withdrawal latency in tail ‰ick test by tail ‰ick analgesiometer. 12) The intensity of the radiant heat was adjusted to obtain a basal or pre-treatment latency of 6 8 s in normal mice. Maximum cutoŠ latency time wasˆxed at 10 s. Tail ‰ick latency was expressed in seconds.
Estimation of Serum Nitrite as Index of Nitric Oxide Production
Nitric oxide (NO) is rapidly oxidized to nitrite/nitrate and its half-life in biological systems is very short. 13) Therefore the measurement of nitrite concentration is routinely used as an index of NO production. 14 16) Serum nitrite levels were estimated by Griess reaction; 17) values are expressed in mmol l -1 .
Preparation of Spleen Homogenate Supernatant
After sacriˆcing the mice by cervical dislocation, the spleen was removed and immersed in 1％ Minimal Essential Media (MEM, pH＝7.8). The spleen was mashed, homogenized, and centrifuged at 3000 rpm for 10 min. The supernatant of spleen homogenate (SHS) was used for the study, in place of mononuclear spleen cells, to avoid any implication of immunogenic response.
EXPERIMENTAL DESIGN
Nine groups were included in the present study, each group comprised six animals.
1) Group I (Non-diabetic control group) Mice were administered citrate buŠer to serve as non-diabetic control animals. Tail ‰ick latency was noted before and after administration of citrate buŠer on days 1, 4, 10, 14, 20, 24 and 30. Serum nitrite levels were noted before and after day 30 of buŠer administration. Fasting glucose levels were monitored before and after administration of citrate buŠer on days 16 and 30.
2) Group II (Streptozotocin-induced diabetic group)
Mice were administered a single dose of STZ (200 mg kg
i.p.) to serve as diabetic control animals. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on the days as described in group I.
3) Group III (Spironolactone-treated diabetic group; 7 mg kg -1 ) Mice were administered spironolactone (7 mg kg -1 i.p.), daily for 14 days, starting on day 16 after STZ administration. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on the days as described in group I. daily) of non-diabetic mice (Group I mice) for 14 days. Tail ‰ick latency was noted before and after administration of SHS on days 1, 2, 4, 8, 10 and 14. Serum nitrite levels and fasting glucose levels were noted before and on day 14 after SHS administration.
(b) Group VI: Non-diabetic mice were administered SHS (1 ml kg -1 daily) of 30 th day diabetic mice (Group II mice) for 14 days. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on the days as described in group V.
(c) Group VII: Non-diabetic mice were administered SHS (1 ml kg -1 daily) of 30 th day diabetic mice, which were treated with spironolactone (7 mg kg -1 i.p.) (Group III mice) for 14 days. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on the days as described in group V.
(d) Group VIII (n＝6): Non-diabetic mice were administered SHS (1 ml kg -1 daily) of 30 th day diabetic mice, which was treated with spironolactone (15 mg kg -1 i.p.) (Group IV mice) for 14 days. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on diŠerent days as described in group V.
(e) Group IX (n＝6): Non-diabetic mice were administered SHS (1 ml kg -1 daily) of 30 th day diabetic mice, which were treated with 0.5％ CMC (Group V mice) for 14 days. Tail ‰ick latency, serum nitrite levels, and fasting glucose levels were noted on the days as described in group V.
Data Analysis All the results are expressed as mean±S.E.M. The data were analyzed by two-way analysis of variance (ANOVA) followed by Tukey's multiple range test. The level of signiˆcance wasˆxed at p＜0.05.
RESULTS

EŠect of Pharmacological Agents on Blood Glucose Levels
A signiˆcant rise in glucose levels was noted in STZ-treated mice as compared with normal non-diabetic mice. Administration of spironolactone did not modulate STZ-induced rise in glucose levels. Administration of SHS of diabetic mice did not aŠect basal glucose levels. Moreover, spironolactone also did not modulate glucose levels in SHS-treated mice ( Table 1) .
EŠect of Spironolactone on Tail Flick Latency Time in Diabetic Mice
As shown in Fig. 1 , tail ‰ick latency time was gradually decreased in STZ-induced diabetic mice compared with non-diabetic mice. Signiˆcant hyperalgesia was noted on and after day 10 following STZ administration, and peak hyperalgesia was noted on day 30.
Administration of spironolactone (7 or 15 mg kg -1 p.o.) for 14 days, starting on day 16 after STZ ad- Each value is mean±S.E.M. for six animals; a＝p＜0.05 vs non diabetic mice; b＝p＜0.05 vs diabetic mice; c＝p＜0.05 vs spironolactone (7 mg/kg) treated.
ministration, signiˆcantly suppressed the further progression of diabetic hyperalgesia.
EŠect of Spironolactone on Serum Nitrite Level in Diabetic Mice
Serum nitrite levels were signiˆcantly increased in diabetic mice measured on day 30 after STZ administration as compared with basal levels (Fig. 2) . Administration of spironolactone (7 mg kg -1 or 15 mg kg -1 p.o.) for 14 days, starting on day 16 after STZ administration, signiˆcantly attenuated STZ induced increase in serum nitrite levels (Fig. 3) .
EŠect of Spleen Homogenate Supernatant (SHS) on Tail Flick Latency Time and Serum Nitrite Levels
Administration of SHS of non-diabetic mice, daily for 14 days, in normal mice did not produce signiˆcant eŠect on tail ‰ick latency time measured on days 1, 2, 4, 8, 10 and 14 and on serum nitrite levels measured on day 14 as compared with basal levels (Figs. 3 and 4) . However, administration of SHS of STZ-induced diabetic mice, daily for 14 days, signiˆcantly decreased tail ‰ick latency time and increased serum nitrite levels in normal mice (Figs. 3  and 4) .
EŠect of Sspleen Homogenate Supernatant (SHS) of Spironolactone-treated Diabetic Mice on Tail Flick Latency Time and Serum Nitrite Levels
Administration of SHS of diabetic mice treated with spironolactone (7 mg kg -1 and 15 mg kg -1 p.o.) did not alter tail ‰ick latency time and serum nitrite levels in normal mice (Figs. 3 and 4) .
DISCUSSION
STZ is a well reported chemical agent to induce insulin-dependent diabetes mellitus (IDDM) in mice. It is reported from our 9, 10, 14) as well as from other laboratories 3) that a signiˆcant degree of hyperalgesia develops in mice after 4 weeks of STZ administration. Therefore in the present study mice were kept for 4 weeks after STZ administration to provide su‹cient time for hyperglycemia to aŠect pain perception.
We observed that nociceptive threshold was signiˆcantly decreased in STZ-induced diabetic mice as assessed by decrease in tail ‰ick latency on diŠerent days and decrease in nociceptive threshold was directly related to duration of hyperglycemia, with peak hyperalgesia observed on day 30 after STZ administration. However, administration of spironolactone signiˆcantly attenuated decrease in nociceptive threshold in STZ-induced diabetic mice without aŠecting blood glucose levels. Clinically, spironolactone has been employed to reduce mortality incidence in patients with congestive heart failure and myocardial infarction. 5, 6) Spironolactone has been reported to ameliorate glomerular injury in STZ-induced diabetic renal injury. 8) However, this is theˆrst report suggesting usefulness of spironolactone in attenuating hyperalgesia in diabetic mice.
In the present investigation, serum nitrite levels were signiˆcantly elevated after day 30 of STZ administration. These results are in consonance with reports from our 14) and from other laboratories. 18) Administration of spironolactone attenuated rise in nitrite levels associated with STZ treatment, indicating decreased production of NO in body. Eplerenone, a novel selective aldosterone blocker, has been documented to downregulate iNOS expression 19) and spironolactone derivatives have also been reported to suppress iNOS in mononuclear cells of mice. 20) Spironolactone is a mineralo-corticoid (aldosterone) receptor antagonist, and is a mild diuretic. There have been several reports demonstrating that spironolactone administration decreases expression of pro-in‰ammatory mediators and cytokines such as TNF-a, IL-6, interferon (IFN)-g, MCP-1, and NFkB. 21, 22) Furthermore, the role of cytokines has been well documented in the pathogenesis of diabetic neuropathy and associated hyperalgesia. 23) Therefore it may be tentatively proposed that spironolactone-mediated decrease in cytokine expression is responsible for its anti-hyperalgesic eŠect noted in the present study. Indeed, cytokines are well documented to increase the production of NO. 24) Therefore spironolactone-mediated attenuation of STZ-induced increase in NO in diabetic mice may be possibly linked to decrease in cytokine production. However, our study does not directly support the hypothesis that antihyperalgesic eŠects of spironolactone in diabetic mice are due to suppression of cytokine generation.
In the present investigation, administration of SHS of 30 th day diabetic mice resulted in induction of hyperalgesia and increase in serum nitrite levels in normal non-diabetic mice. These results suggest that certain factors are released from spleen during diabetes, which contribute signiˆcantly to induction of hyperalgesia. These results are in consonance with our earlier report. 10) However, administration of SHS of spironolactone-treated diabetic mice failed to induce hyperalgesia and to increase serum nitrite levels. It is possible to suggest that spironolactone may have inhibited the production of spleen-derived factors involved in the induction of hyperalgesia in diabetic mice.
Spleen is a principal organ of the immune system and a rich source of cytokines. Long-standing hyperglycemia is reported to induce cytokine production from mononuclear cells. 25, 26) There have been several reports suggesting the presence of mineralo-corticoid and glucocorticoid receptors (45 and 600 fmol/mg protein, respectively) in splenic cells and mononuclear in‰ammatory cells. 27 31) Spironolactone is documented to attenuate cytokine production from mononuclear cells. 32) Therefore in the present investigation the anti-hyperalgesic eŠect of spironolactone may be indirectly linked to decrease in cytokine production by blocking mineralo-corticoid receptors present on mononuclear cells in the spleen. However, there have been reports suggesting that the suppressive eŠect of spironolactone on immune-reactive and in‰ammatory cytokines is independent of mineralocorticoid receptors blockade. 33, 34) It may be tentatively hypothesized that hyperglycemia in diabetic mice triggers cytokine generation from mononuclear cells in spleen, and spironolactone causes anti-hyperalgesic eŠects possibly due to decrease in cytokine generation from mononuclear cells in spleen.
CONCLUSION
Spironolactone has ameliorative potential in attenuating diabetic hyperalgesia, which may be possibly linked to interference with release of spleen-derived factors involved in the pathogenesis of diabetic hyperalgesia.
